A Literature Review Into The Role Of DNA Methylation As An Epigenetic Factor In Type 2 Diabetes

Insights into the Pathogenesis and Emerging Therapeutic Targets of T2D

Abstract

Type 2 diabetes (T2D) is a complex metabolic condition that is influenced not only by genetics and lifestyle but also by DNA methylation, an epigenetic factor. This review investigates how irregular methylation patterns in pancreatic islets, adipose tissue, liver, and skeletal muscle can disrupt insulin signaling, impair glucose uptake, and alter metabolic pathways, which all have contributed significantly to the development of T2D. Environmental and lifestyle factors, including diet, physical activity, stress, and early-life exposures, are also explored, all of which can affect DNA methylation patterns. Many alterations in DNA methylation are reversible, creating potential for interventions such as healthy diets and targeted therapies to reverse these changes in the body. This review evaluates the current evidence on the role of DNA methylation in the pathogenesis of T2D, how it interacts with environmental factors, and the therapeutic potential of targeting these epigenetic modifications. There are many emerging therapeutic options, including nutritional epigenomics, pharmacological agents (e.g., metformin, hydralazine), and natural compounds (e.g., curcumin); these show promise in modifying methylation to prevent or manage disease. There are still challenges in determining causality, addressing tissue-specific variability, and identifying universal biomarkers. We think longitudinal studies tracking individuals from their early life, alongside personalized approaches based on individual epigenetic profiles, would be the most effective next steps in reducing T2D risk through methylation-based strategies.